Market News AIOpen the app

MIRM stock news · Mirum Pharmaceuticals, Inc.

Stories about Mirum Pharmaceuticals, Inc. (MIRM) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for MIRM

Follow Mirum Pharmaceuticals, Inc. (MIRM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MIRM
Free on the App Store and Google Play, or on the web.
  1. Oct 13, 2026, 8:26 AM ET · Trial

    Mirum Pharmaceuticals shares news about its successful Phase 3 study of LIVMARLI.

    Good for MIRM

    Mirum reported successful Phase 3 results for LIVMARLI in rare liver diseases. The results support possible use in more patients, though diarrhea was more common and a U.S. filing is planned for 2027.

  2. Oct 12, 2026, 9:42 AM ET · Market

    Mirum Pharmaceuticals' stock is going up today after good news about its drug LIVMARLI.

    Good for MIRM

    Mirum's Phase 3 study met its main goal and all 5 additional measures, with better itching and bile-acid results than placebo. This is favorable news for LIVMARLI.

  3. Oct 12, 2026, 8:17 AM ET · Market

    12 health care companies are changing prices before the market opens on Monday.

    Neutral

    Mirum Pharmaceuticals shares rose about 13% before Monday's open, but the article gives no business reason, so its outlook is unchanged.